BioXcel Therapeutics (BTAI) Misses Q2 EPS by 16c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q2 EPS of ($1.83), $0.16 worse than the analyst estimate of ($1.67). Revenue for the quarter came in at $457 thousand versus the consensus estimate of $420.56 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Benchmark Reiterates Speculative Buy Rating on Nephros (NEPH) Following Strong Q2 Results
• TD Cowen Reiterates Buy Rating on NVIDIA (NVDA), 'unlikely to move significantly on earnings'